Key result
Sotatercept improves pulmonary vascular resistance and walking distance in Japanese patients with PAH.
Why the study?
Does sotatercept improve pulmonary vascular resistance and 6-minute walk distance in Japanese patients with pulmonary arterial hypertension?
Does sotatercept improve pulmonary vascular resistance and 6-minute walk distance in Japanese patients with pulmonary arterial hypertension?
Sotatercept improves pulmonary vascular resistance and 6-minute walk distance in Japanese patients with PAH, extending the findings of the global STELLAR trial to this population.
Answers are grounded in this paper and cite their sources.
May support sotatercept in Japanese PAH patients; extends STELLAR findings but leaves efficacy open to randomized confirmation.
In this study of Japanese participants with PAH, improvements in pulmonary vascular resistance and 6-minute walk distance were observed, consistent with the pivotal phase 3 STELLAR (A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension [MK-7692-003/A011-11]) trial. These data suggest that sotatercept may be an important treatment option for Japanese patients with PAH. (A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension [PAH] Participants [MK-7962-020], NCT05818137; Japan Registry of Clinical Trials [jRCT2031230046]).
No takes yet. Share an insight, caveat, or question.
Matsubara et al. (2026) studied Pulmonary Arterial Hypertension. Sotatercept was evaluated on Pulmonary vascular resistance and 6-minute walk distance. Sotatercept improved pulmonary vascular resistance and walking distance in Japanese participants with pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: